Firmagon

Firmagon

degarelix

Manufacturer:

Ferring

Distributor:

Zuellig Pharma
Concise Prescribing Info
Contents
Degarelix
Indications/Uses
Advanced hormone-dependent prostate cancer in adult male.
Dosage/Direction for Use
Initially 240 mg administered as 2 SC inj of 120 mg each. Maintenance: 80 mg administered as 1 SC inj (mthly administration).
Contraindications
Hypersensitivity. Pregnancy & lactation. Women, childn & adolescents.
Special Precautions
Long-term androgen deprivation therapy may prolong QT interval. History of corrected QT interval >450 millisec, Torsades de pointes. Concomitant w/ medicines that prolong QT interval. History of severe untreated asthma, anaphylactic reactions or severe urticaria or angioedema. Decreased bone density & glucose tolerance in men who had orchiectomy or treated w/ GnRH agonist. Severe hepatic & renal impairment. May impair ability to drive or operate machinery.
Adverse Reactions
Hot flushes, inj site reactions, anaemia, increased wt, insomnia, dizziness, headache, diarrhoea, nausea, increased liver transaminases, hyperhidrosis, rash, musculoskeletal pain & discomfort, gynaecomastia, testicular atrophy, erectile dysfunction, chills, pyrexia, fatigue, influenza-like illness.
Drug Interactions
Quinidine, disopyramide, amiodarone, sotalol, dofetilide, ibutilide, antiarrhythmics, methadone, cisapride, moxifloxacine, antipsychotics.
ATC Classification
L02BX02 - degarelix ; Belongs to the class of other hormone antagonists and related agents. Used in the treatment of advanced prostate cancer.
Presentation/Packing
Form
Firmagon powd for inj 80 mg
Packing/Price
(+ 4.2 mL solvent) 1's
Form
Firmagon powd for inj 120 mg
Packing/Price
(+ 3 mL solvent) 2's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in